SG11201805579SA - Recombinant igg fc multimers - Google Patents
Recombinant igg fc multimersInfo
- Publication number
- SG11201805579SA SG11201805579SA SG11201805579SA SG11201805579SA SG11201805579SA SG 11201805579S A SG11201805579S A SG 11201805579SA SG 11201805579S A SG11201805579S A SG 11201805579SA SG 11201805579S A SG11201805579S A SG 11201805579SA SG 11201805579S A SG11201805579S A SG 11201805579SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- multimers
- bern
- strasse
- english
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 010111110111011101111110111111001111111110111011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....1 WO 2017/129737 Al 3 August 2017 (03.08.2017) WI P0 I P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/00 (2006.01) A61P 37/00 (2006.01) C07K 16/00 (2006.01) C07K 16/14 (2006.01) A61K 39/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: PCT/EP2017/051757 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: 27 January 2017 (27.01.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 16152867.4 27 January 2016 (27.01.2016) EP 16162166.9 24 March 2016 (24.03.2016) EP 16195116.5 21 October 2016 (21.10.2016) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: CSL BEHRING RECOMBINANT FACIE- ITY AG [CH/CH]; Wankdorfstrasse 10, 3014 Bern (CH). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, _ (72) Inventors: SPIRIG, Rolf; Landoltstrasse 83, 3007 Bern (CH). KAESERMANN, Fabian; Alpenstrasse 41, 3400 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — _ Burgdorf (CH). ZUERCHER, Adrian; Stapfenacker- strasse 95, 3018 Bern (CH). PANOUSIS, Con; 88 Linacre Published: Drive, Bundoora, 3085 (AU). BAZMORELLI, Adriana; with international search report (Art. 21(3)) 1106/604 Swanston St, Carlton, 3053 (AU). CHEN, — with sequence listing part of description (Rule 5.2(a)) . Chao-Guang; 51 Strickland Road, Parkville, 3052 (AU). Agents: PETER, Beate et al.; Emil-von-Behring-Strasse = (74) 76, 35041 Marburg (DE). = = = = = = = = Il IN M IN 01 N 1-1 IN 1-1 0 \" (54) Title: RECOMBINANT IGG FC MULTIMERS C ) ,..,.. (57) : This disclosure provides recombinant IgG Fc multimers and methods of treating autoimmune and inflammatory dis - .,- eases by administering such multimers.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152867 | 2016-01-27 | ||
| EP16162166 | 2016-03-24 | ||
| EP16195116 | 2016-10-21 | ||
| PCT/EP2017/051757 WO2017129737A1 (en) | 2016-01-27 | 2017-01-27 | Recombinant igg fc multimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805579SA true SG11201805579SA (en) | 2018-08-30 |
Family
ID=57956274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805579SA SG11201805579SA (en) | 2016-01-27 | 2017-01-27 | Recombinant igg fc multimers |
| SG10201911561SA SG10201911561SA (en) | 2016-01-27 | 2017-01-27 | Recombinant igg fc multimers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911561SA SG10201911561SA (en) | 2016-01-27 | 2017-01-27 | Recombinant igg fc multimers |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190119377A1 (en) |
| EP (1) | EP3408279A1 (en) |
| JP (1) | JP2019511458A (en) |
| KR (1) | KR20180100701A (en) |
| CN (1) | CN108602857A (en) |
| AU (1) | AU2017213117A1 (en) |
| BR (1) | BR112018014668A2 (en) |
| CA (1) | CA3012037A1 (en) |
| HK (1) | HK1258166A1 (en) |
| MX (1) | MX2018008339A (en) |
| RU (1) | RU2018130525A (en) |
| SG (2) | SG11201805579SA (en) |
| WO (1) | WO2017129737A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116970060A (en) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T cell modulating multimeric polypeptides and methods of use thereof |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| JP2020514375A (en) | 2017-03-15 | 2020-05-21 | キュー バイオファーマ， インコーポレイテッド | Methods for modulating the immune response |
| WO2019098212A1 (en) | 2017-11-14 | 2019-05-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| DK3723791T3 (en) | 2017-12-14 | 2024-04-08 | CSL Behring Lengnau AG | RECOMBINANT IGG-FC MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| WO2020102251A1 (en) * | 2018-11-14 | 2020-05-22 | Jn Biosciences Llc | Multimeric hybrid fc proteins for replacement of ivig |
| CN113260375B (en) | 2018-12-13 | 2024-10-01 | 阿尔金克斯有限公司 | Antibodies to human complement factor C2b and methods of use |
| CA3150680A1 (en) | 2019-09-13 | 2021-03-18 | Helen Zhihui CAO | Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders |
| KR20220066075A (en) * | 2019-09-20 | 2022-05-23 | 큐 바이오파마, 인크. | T-cell regulatory polypeptides and methods of use thereof |
| US20240092889A1 (en) * | 2019-10-16 | 2024-03-21 | Chugai Seiyaku Kabushiki Kaisha | An antibody, a pharmaceutical composition, and a method |
| WO2021111007A1 (en) | 2019-12-06 | 2021-06-10 | CSL Behring Lengnau AG | Stable compositions of fc multimers |
| TW202208395A (en) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2023541366A (en) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | MHC class II T cell modulating multimeric polypeptides and methods of use thereof to treat type 1 diabetes mellitus (T1D) |
| CN114894911B (en) * | 2022-03-18 | 2023-10-24 | 辽宁成大生物股份有限公司 | Method for controlling quality of bovine serum products |
| CN115112879A (en) * | 2022-07-01 | 2022-09-27 | 重庆艾生斯生物工程有限公司 | Conjugate and application thereof in immunoassay |
| CN118027155B (en) * | 2024-04-15 | 2024-07-16 | 中国人民解放军军事科学院军事医学研究院 | TPOR binding peptide and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205363B2 (en) * | 2011-09-26 | 2017-09-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | Hybrid stationary region |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| CN110894231A (en) * | 2012-10-17 | 2020-03-20 | 康诺贝林伦瑙有限公司 | Immunomodulatory proteins |
| MX2016010951A (en) * | 2014-03-05 | 2016-11-29 | Ucb Biopharma Sprl | Multimeric fc proteins. |
| KR20160127821A (en) * | 2014-03-05 | 2016-11-04 | 유씨비 바이오파마 에스피알엘 | Multimeric fc proteins |
-
2017
- 2017-01-27 SG SG11201805579SA patent/SG11201805579SA/en unknown
- 2017-01-27 AU AU2017213117A patent/AU2017213117A1/en not_active Abandoned
- 2017-01-27 EP EP17702590.5A patent/EP3408279A1/en not_active Withdrawn
- 2017-01-27 RU RU2018130525A patent/RU2018130525A/en not_active Application Discontinuation
- 2017-01-27 SG SG10201911561SA patent/SG10201911561SA/en unknown
- 2017-01-27 JP JP2018539140A patent/JP2019511458A/en active Pending
- 2017-01-27 CA CA3012037A patent/CA3012037A1/en not_active Abandoned
- 2017-01-27 BR BR112018014668-4A patent/BR112018014668A2/en not_active IP Right Cessation
- 2017-01-27 MX MX2018008339A patent/MX2018008339A/en unknown
- 2017-01-27 KR KR1020187024678A patent/KR20180100701A/en unknown
- 2017-01-27 CN CN201780008312.9A patent/CN108602857A/en active Pending
- 2017-01-27 US US16/072,678 patent/US20190119377A1/en not_active Abandoned
- 2017-01-27 WO PCT/EP2017/051757 patent/WO2017129737A1/en active Application Filing
-
2019
- 2019-01-14 HK HK19100521.7A patent/HK1258166A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017213117A1 (en) | 2018-07-19 |
| BR112018014668A2 (en) | 2018-12-11 |
| CA3012037A1 (en) | 2017-08-03 |
| US20190119377A1 (en) | 2019-04-25 |
| JP2019511458A (en) | 2019-04-25 |
| SG10201911561SA (en) | 2020-02-27 |
| EP3408279A1 (en) | 2018-12-05 |
| MX2018008339A (en) | 2018-09-17 |
| HK1258166A1 (en) | 2019-11-08 |
| RU2018130525A (en) | 2020-02-27 |
| KR20180100701A (en) | 2018-09-11 |
| RU2018130525A3 (en) | 2020-05-29 |
| WO2017129737A1 (en) | 2017-08-03 |
| CN108602857A (en) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201909331UA (en) | Antigen-specific immune effector cells | |
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis |